title: Salmon calcitonin in the treatment of elderly women with type 2 diabetes complicated with osteoporosis.
abstract: To explore the reasonable treatment scheme of salmon calciteonin in the treatment of elderly women with type 2 diabetes complicated with osteoporosis, patients were randomly divided into Group A, B and C, and they were given the salmon calcitonin every time 50 IU, subcutaneous injection. The Group A were 1 time a day, for 15 days; Group B were 1 time every 2 days, for 30 days; Group C, one time three days for 90 days. Then to observe the symptoms have efficiency, bone density T value change, incidence rate, incidence of side effects and treatment of loss rate of fracture. Efficiency of symptoms: Group A is lower and there is no difference in Group B and C. T Degree: Group C was significantly increased and Group A was the lowest. Fracture incidence of Group B and C were significantly lower than Group A, and there is no difference in Group B and C. Turnover rate: Group A was significantly lower than B and C, and there is no difference in Group B and C. There is low incidence of side effects in the three groups and they three have no significant difference. It is effective and safe to use salmon calcitonin in the treatment of elderly women with type 2 diabetes complicated with osteoporosis. 50 IU each time, subcutaneous injection, 1 time every 3 days, for 3 months is a reasonable solution.
authors.affiliation: Department of endocrinology, The First Affiliated Hospital, Zhengzhou University, Hen Nan Province, China / Department of endocrinology, The First Affiliated Hospital, Nanyang Medical College, Hen Nan Province, China.
authors.forename: Liu
authors.initials: L
authors.lastname: Dexue
authors.affiliation: Department of endocrinology, The First Affiliated Hospital, Nanyang Medical College, Hen Nan Province, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Yueyue
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D050071:Bone Density Conservation Agents; C028815:salmon calcitonin; D002116:Calcitonin